You need to create a user account to read this article.
With a subscription you unlock more content on BioStock.
New positive data from Guard Therapeutics AKITA study
Text:
Kim Liedholm | [email protected]
Guard Therapeutics has reported new positive efficacy data from secondary analyses of the Phase IIa study evaluating the drug candidate RMC-035 as a nephroprotective treatment in open heart surgery. The results confirm and expand on the previous...